Pharvaris N.V.
NASDAQ: PHVS0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Berndt Modig
- Employees
- 129
- Headquarters
- Leiden, Netherlands
- IPO year
- 2021
- Market cap
- $2.3B
- Website
- https://pharvaris.com
Loading PHVS…
Loading profile data…Frequently asked questions about PHVS
What does Pharvaris N.V. (PHVS) do?
Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated ang...
Where does PHVS trade?
Pharvaris N.V. (PHVS) trades on the NASDAQ.
What sector is PHVS in?
Pharvaris N.V. (PHVS) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pharvaris N.V.?
Berndt Modig is the chief executive officer of Pharvaris N.V. (PHVS).
Where is Pharvaris N.V. headquartered?
Pharvaris N.V. is headquartered in Netherlands.
Does PHVS pay a dividend?
Pharvaris N.V. (PHVS) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did PHVS go public?
Pharvaris N.V. (PHVS) completed its initial public offering in 2021.